London-based Verdiva Bio launches with 398.4M to challenge Ozempic's reign in obesity treatment - Silicon CanalsVerdiva Bio launches with $411M funding to develop innovative therapies for obesity and cardiometabolic disorders.Leading therapy, VRB-101, shows strong efficacy in initial trials.